In a groundbreaking development, 18-month-old Opal Sandy from Oxfordshire hears almost perfectly after receiving pioneering gene therapy for auditory neuropathy. The procedure, which took just 16 minutes, marks a new era in treating deafness. Doctors at Addenbrooke’s hospital, Cambridge, are running the Chord trial, recruiting deaf children from the UK, Spain, and the US. Prof. Manohar Bance, the trial's chief investigator, expresses optimism, stating the results are better than expected. The therapy, using a working copy of the OTOF gene, is a potential cure. Opal is the first patient globally to undergo this treatment, offering hope for others.

Parents of deceased daughters plan to sue AstraZeneca after it admitted Covishield's rare side effects in UK court. Venugopalan Govindan criticizes Serum Institute for not stopping supply despite European restrictions. He promises legal action if justice isn't served. Rachana Gangu, another parent, requests a medical probe and compensation. AstraZeneca faces a UK lawsuit over alleged vaccine-related deaths and injuries, acknowledging rare clotting issues. Grieving parents demand accountability from vaccine makers and government authorities for vaccine approval.

A study presented at the ESCMID Global Congress reveals the presence of pathogenic bacteria and fungi, including multidrug-resistant "superbugs," on surfaces of UK hospital toilets. Led by Professor Stephanie Dancer, the research found patient toilets to be worst affected, posing significant health threats. Women's bathrooms exhibited fewer microbes than men's, attributed to gender disparities in hygiene habits. Gram-negative pathogens were found on various surfaces due to aerosolization during flushing. Recommendations include closing toilet lids before flushing and prioritizing hand hygiene education. The findings underscore the importance of improved hygiene practices in healthcare settings.

Former ICMR scientist Dr. Raman Gangakhedkar reassures that only 7 to 8 individuals out of 10 lakh vaccinated with Covishield face the rare side effect of thrombosis thrombocytopenia syndrome (TTS). He highlights that the risk is highest after the first dose but decreases with subsequent doses. Gangakhedkar emphasizes the vaccine's overall positive impact on millions, despite AstraZeneca's acknowledgment of rare blood clotting side effects. With at least 90% of Indians inoculated with Covishield, Gangakhedkar urges understanding of the minimal risk compared to the vaccine's widespread benefits.

Amidst concerns over rare blood clot side effects, AstraZeneca reiterates its focus on patient safety for its Covid-19 vaccine. The UK-headquartered pharmaceutical company extends sympathy to affected individuals while stressing adherence to stringent regulatory standards. AstraZeneca's vaccine, known as Covishield in India, faces scrutiny after acknowledging the potential for clot-related side effects in very rare cases. Court documents reveal the admission, although the causal link remains unclear. The World Health Organization identifies thrombosis with thrombocytopenia syndrome (TTS) as a new adverse event post-immunization with adenovirus vector-based Covid-19 vaccines. AstraZeneca maintains its commitment to safety amidst ongoing investigations into the vaccine's rare side effects.

Three women got HIV after a "vampire facial" at a New Mexico spa in 2018, says Centers for Disease Control and Prevention (CDC). The spa was not licensed and had unsafe practices. The facial injects platelet-rich plasma into the face to make skin look better. It's important to handle blood safely to avoid infections. Owner Maria de Lourdes Ramos De Ruiz got prison time for doing medicine without a license. Health experts say be careful and research before doing cosmetic treatments. There's also a warning about fake Botox causing illness.

AstraZeneca acknowledges its Covid-19 vaccine can lead to Thrombosis with Thrombocytopenia Syndrome (TTS), causing blood clots and low platelet count. While facing litigation over related claims, the rare side effect concerns millions globally, including India. Experts reassure the risk is minimal, with occurrences typically within a month after vaccination. Dr. Sudhir Kumar, a Neurologist at Apollo Hospital in Hyderabad, highlights TTS rarity despite millions vaccinated. Both vaccines, Covishield and Covaxin, are deemed effective, with no significant data favoring one over the other. Rare side effects include Guillain Barre syndrome and cerebral venous sinus thrombosis. AstraZeneca vaccine suspensions occurred globally due to clotting concerns.

In a legal battle, AstraZeneca admits its Covid-19 vaccine, including brands Covishield and Vaxzevria, can cause rare side effects like Thrombosis with Thrombocytopenia Syndrome (TTS), involving blood clots and low platelet counts. The pharmaceutical giant faces a class-action lawsuit over alleged serious injuries and deaths. A pivotal moment in the case, AstraZeneca's admission underscores potential risks associated with vaccination. The company's concession follows extensive legal disputes and could result in significant payouts. Despite acknowledging rare side effects, AstraZeneca maintains its vaccine's efficacy while the UK discontinues its use due to safety concerns.            

A study by leading disease specialists suggests that a strain of the flu virus is highly likely to spark the next major global pandemic, with 57% of experts in agreement. This prediction is based on the flu virus's constant evolution and mutation, posing a persistent threat. The findings, set to be unveiled at a medical conference, stress the ongoing danger posed by flu outbreaks worldwide. Additionally, 21% of specialists see "Disease X," an unknown pathogen akin to COVID-19, as another potential pandemic source.

The World Health Organization (WHO) expresses grave concern as the H5N1 bird flu strain spreads to new species, including humans. WHO's chief scientist warns of a global zoonotic animal pandemic as the virus infects mammals like cows and goats. While no evidence of human-to-human transmission exists, the mortality rate among infected individuals is "extraordinarily high" at 52%. With 463 deaths recorded from 889 human cases across 23 states in the last 15 months, WHO emphasizes the virus's potential to evolve and infect new hosts, heightening global health risks.